Key Points
- Insider Mark Sabag sold 46,000 Teva shares for about $1.93 million at an average price of $41.93, reducing his holdings by 36.29% to 80,760 shares.
- Teva reported quarterly EPS of $0.86, beating the $0.72 analyst consensus, and revenue of $4.39 billion versus $4.23 billion expected; revenue was down 1.9% year over year.
- Analyst sentiment was broadly positive: 13 analysts rated TEVA a Buy, with a consensus “Moderate Buy” rating and a $47.23 price target. Leerink Partners raised its target from $45 to $52 and maintained an “outperform” rating.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Mark Sabag sold 46,000 shares of the business's stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the sale, the insider owned 80,760 shares of the company's stock, valued at $3,386,266.80. This represents a 36.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Teva Pharmaceutical Industries Stock Performance
TEVA stock opened at $42.52 on Friday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $23.61 and a 52 week high of $43.34. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The firm has a 50 day simple moving average of $39.49 and a 200 day simple moving average of $34.79. The stock has a market cap of $49.55 billion, a P/E ratio of 98.88, a P/E/G ratio of 3.77 and a beta of 0.97.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.14. The business had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. The firm's quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.78 earnings per share. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Teva Pharmaceutical Industries
Several institutional investors have recently bought and sold shares of the business. Aberdeen Group plc grew its position in Teva Pharmaceutical Industries by 28.1% during the third quarter. Aberdeen Group plc now owns 103,897 shares of the company's stock valued at $4,114,000 after buying an additional 22,814 shares during the period. EagleClaw Capital Managment LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $206,000. Russell Investments Group Ltd. increased its stake in Teva Pharmaceutical Industries by 6.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 453,785 shares of the company's stock valued at $17,969,000 after buying an additional 26,341 shares during the period. Ritholtz Wealth Management raised its position in Teva Pharmaceutical Industries by 7.9% during the third quarter. Ritholtz Wealth Management now owns 22,103 shares of the company's stock valued at $875,000 after buying an additional 1,613 shares during the period. Finally, Jefferies Financial Group Inc. lifted its position in shares of Teva Pharmaceutical Industries by 65.5% during the 3rd quarter. Jefferies Financial Group Inc. now owns 75,000 shares of the company's stock worth $2,970,000 after purchasing an additional 29,696 shares during the last quarter. Institutional investors own 54.05% of the company's stock.
Analysts Set New Price Targets
TEVA has been the subject of a number of analyst reports. Leerink Partners upped their price objective on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an "outperform" rating in a research report on Thursday. Zacks Research lowered shares of Teva Pharmaceutical Industries from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 20th. Oppenheimer raised their price objective on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an "outperform" rating in a research note on Friday, October 9th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday. Finally, Barclays increased their price target on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an "overweight" rating in a report on Thursday, October 15th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.23.
View Our Latest Research Report on TEVA
Trending Headlines about Teva Pharmaceutical Industries
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
- Positive Sentiment: Teva’s third-quarter earnings beat estimates, and the company raised its 2026 revenue and product-sales outlook, citing strong branded-drug sales. Revenue was slightly lower year over year, but the results and upgraded outlook were encouraging. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
- Positive Sentiment: A report highlighted 33% sales growth last quarter across Teva’s three key branded medicines, alongside improved margins and net-debt reduction—factors that could strengthen earnings and the balance sheet. Article: Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter
- Positive Sentiment: Leerink Partners raised its price target to $52 from $45 and maintained an “outperform” rating, signaling greater analyst confidence in potential upside. Article: Leerink Partners Raises Teva Price Target
- Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $52 target and projected 2027 EPS of $3.03, well above its 2026 estimate of $1.94. Teva analyst estimates
- Negative Sentiment: Insider Mark Sabag sold 46,000 shares for about $1.93 million, reducing his direct holdings by 36.29%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC insider transaction filing
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas.
Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Teva is headquartered in Tel Aviv, Israel.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
